Fulcrum Therapeutics, Inc. (FULC)

Nasdaq: FULC · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2016

Full chart Alerts Compare

Grade5.2

◀ Past 4.7● Present 6.2▶ Future 4.7

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Fulcrum Therapeutics, Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.2/10

◀ Past4.725% of the headline

● Present6.235% of the headline

▶ Future4.740% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Fulcrum Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.0/10

What has it actually done, year after year?

6 filed years; profitable in 0 of 4.

weight 45% of this tense · 20th percentile among 323 sector filers · read for its customers

From the record

Fulcrum Therapeutics, Inc.'s 6 filed years say what it did: it rose in 2 of 5 years; the deepest fall was 100% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

the share of years revenue rosebottom 24% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

6.1/10

How has it treated the people who own it?

SI estimate 6.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 61st percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 39% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Fulcrum Therapeutics, Inc.'s shareholder treatment is put at 6.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 39% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

6.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

8.2/10

Is it financially healthy right now?

ROE -21%: lost 21¢ per shareholder dollar. Leverage 5%: owes 5¢ per asset dollar.

weight 45% of this tense · 82nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Fulcrum Therapeutics, Inc. lost about 21 cents for every dollar of shareholders' money. Leverage: it owed about 5 cents per dollar of assets, and net share issuance: its share count grew 2.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 4% of its family
return on equitytop 27% of its family
the share count against the year beforetop 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate

5.2/10

How strong is its position in its industry?

SI estimate 5.2/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 315 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one.
What the record cannot read: No filed revenue on file.
How it was reasoned: family median, 315 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Fulcrum Therapeutics, Inc.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

as filed

4.0/10

What are the people in charge doing?

bottom 40% of 315 in its family for leadership; chief executive since 2023.

weight 33% of this tense · 40th percentile among 315 sector filers · read for its shareholders

From the record

Fulcrum Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sapir, Alex (President & Chief Executive Officer, as filed), filing under that title since 2023-07-03, 3.4 years (bottom 37% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 34%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 13 peopletop 50% of its family
the median years the people in charge have filed4.9 yearsbottom 34% of its family
the chief executive's years on the record3.4 yearsbottom 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.7/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate

6.9/10

How much room does it have to grow?

SI estimate 6.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 69th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the top 31% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Fulcrum Therapeutics, Inc.'s room to expand is put at 6.9 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 31% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed

2.7/10

What could actually drive growth from here?

bottom 27% of 306 in its family for growth drivers.

weight 45% of this tense · 27th percentile among 306 sector filers · read for its customers

From the record

Fulcrum Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: research spending grew -9.9% a year (bottom 31%); capital spending grew -45.7% a year (bottom 24%) (its annual reports). Fulcrum Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth of research spending-9.9%bottom 31% of its family
three-year growth of capital spending-45.7%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Fulcrum Therapeutics, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton FULC · research, not advice